NPJ Vaccines最新文献_第3页

Benefit risk considerations for African swine fever virus live attenuated vaccines. 非洲猪瘟病毒减毒活疫苗的获益风险考虑。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-07 DOI: 10.1038/s41541-025-01208-8

Sandra Blome, Virginia Friedrichs, Alexander Schäfer, Martin Beer

引用次数: 0

A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice. 一种新型的基于gmma的淋球菌疫苗在小鼠中显示出功能性免疫反应。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-05 DOI: 10.1038/s41541-025-01190-1

Marco Spinsanti, Elisabetta Monaci, Giacomo Romagnoli, Giada Buffi, Andrea Guido Oreste Manetti, Filippo Carboni, Giovanna Tuscano, Lucia Eleonora Fontana, Sara Tomei, Marta Zambelli, Rossella Cuffaro, Marianna Taccone, Chiara Sammicheli, Claudia Gianfaldoni, Francesca Angiolini, Maria Giuliani, Sara Marchi, Silvia Senesi, Christian Matano, Ivan Pisoni, Nathalie Norais, Maria Rosaria Romano, Silvia Rossi Paccani, Silvana Savino, Alessandro Muzzi, Federico Fontani, Davide Serruto, Michela Brazzoli, Giulia Giordano, Monica Fabbrini, Ugo D'Oro, Oretta Finco, Immaculada Margarit, Isabel Delany, Erika Bartolini

{"title":"A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice.","authors":"Marco Spinsanti, Elisabetta Monaci, Giacomo Romagnoli, Giada Buffi, Andrea Guido Oreste Manetti, Filippo Carboni, Giovanna Tuscano, Lucia Eleonora Fontana, Sara Tomei, Marta Zambelli, Rossella Cuffaro, Marianna Taccone, Chiara Sammicheli, Claudia Gianfaldoni, Francesca Angiolini, Maria Giuliani, Sara Marchi, Silvia Senesi, Christian Matano, Ivan Pisoni, Nathalie Norais, Maria Rosaria Romano, Silvia Rossi Paccani, Silvana Savino, Alessandro Muzzi, Federico Fontani, Davide Serruto, Michela Brazzoli, Giulia Giordano, Monica Fabbrini, Ugo D'Oro, Oretta Finco, Immaculada Margarit, Isabel Delany, Erika Bartolini","doi":"10.1038/s41541-025-01190-1","DOIUrl":"10.1038/s41541-025-01190-1","url":null,"abstract":"Gonorrhea, caused by Neisseria gonorrhoeae (GC) represents a significant public health threat that may be mitigated by an effective vaccine. Vaccines containing N. meningitidis outer membrane vesicles (OMVs), such as 4CMenB, demonstrated moderate effectiveness in preventing GC infections. Here, we developed NgG, an investigational GC vaccine based on Generalized Modules for Membrane Antigens (GMMA). NgG includes genetically detoxified OMVs from the FA1090 strain, engineered to reduce endotoxin activity and limit immune interference. NgG induced a robust immune response in mice and outperformed the comparator vaccine 4CMenB in several serological and functional tests. Immunization with GMMA from a FA1090 mutant, where major oligosaccharide epitopes are incomplete or absent, revealed that NgG lipooligosaccharide plays a major role in the breadth of functional responses, with protein component also contributing in some GC strains. These results suggest that NgG has the potential to block GC infection through various mechanisms, supporting further vaccine development.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"146"},"PeriodicalIF":6.9,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hamsters immunized with formalin-inactivated SARS-CoV-2 develop accelerated lung histopathological lesions and Th2-biased response following infection. 用福尔马林灭活的SARS-CoV-2免疫的仓鼠在感染后出现加速的肺部组织病理学病变和th2偏向性反应。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-04 DOI: 10.1038/s41541-025-01160-7

Rineke de Jong, Sandra Vreman, Katrin E Wiese, Nora M Gerhards, Kevin R Bewley, Yper Hall, Francisco Javier Salguero, Miles Carroll, Rik L de Swart, Jose L Gonzales, Nadia Oreshkova

{"title":"Hamsters immunized with formalin-inactivated SARS-CoV-2 develop accelerated lung histopathological lesions and Th2-biased response following infection.","authors":"Rineke de Jong, Sandra Vreman, Katrin E Wiese, Nora M Gerhards, Kevin R Bewley, Yper Hall, Francisco Javier Salguero, Miles Carroll, Rik L de Swart, Jose L Gonzales, Nadia Oreshkova","doi":"10.1038/s41541-025-01160-7","DOIUrl":"10.1038/s41541-025-01160-7","url":null,"abstract":"One of the concerns regarding vaccine safety during the COVID-19 pandemic was the potential manifestation of vaccine-associated enhancement of disease (VAED) upon SARS-CoV-2 infection. To investigate the suitability of the Syrian hamster model to test for VAED, we immunized animals with an experimental formaldehyde-inactivated, alum-adjuvanted SARS-CoV-2 vaccine preparation. In two independent experiments, challenge infection did not result in an enhancement of the clinical disease in vaccinated animals compared with mock-vaccinated animals. However, at early timepoints (2-5 days) post-challenge, lung histopathology progressed faster and was more prominent in vaccinated hamsters and lung tissue showed elevated mRNA levels of IL-4 and IL-13. At later time points, cytokine responses and lung pathology were comparable between vaccinated and mock-vaccinated hamsters, underscoring the transient nature of the pathological aggravation. With this work we show that the Syrian hamster model can be used to assess possible vaccine safety considerations in a preclinical setting.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"145"},"PeriodicalIF":6.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity. 优化后的慢病毒主干诱导抗新抗原的强大和多样化的T细胞免疫，以抵消肿瘤的异质性。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-04 DOI: 10.1038/s41541-025-01199-6

Benjamin Vesin, Ingrid Fert, Amandine Noirat, Pierre Authié, Sylvain Ciret, Catherine Blanc, Yakov Vitrenko, Pierre Charneau, Laleh Majlessi, François Anna

{"title":"Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity.","authors":"Benjamin Vesin, Ingrid Fert, Amandine Noirat, Pierre Authié, Sylvain Ciret, Catherine Blanc, Yakov Vitrenko, Pierre Charneau, Laleh Majlessi, François Anna","doi":"10.1038/s41541-025-01199-6","DOIUrl":"10.1038/s41541-025-01199-6","url":null,"abstract":"Targeting personalized tumor neoantigens is a promising strategy in immuno-oncotherapy, tumor heterogeneity requires that adaptive immunity be effectively induced against a broad spectrum of neoantigens for a significant anti-tumor effect. We developed several non-integrative lentiviral vectors encoding optimized immunogen that induce robust T cell responses against neoepitopes derived from murine colorectal tumors. Incorporating proteasome-targeting sequences and 4-alanine spacers between neoepitopes enhanced responses to both dominant and subdominant neoepitopes. Using longer natural sequences encompassing minimal epitopes further improved immunogenicity. These vectors drove complete regression of MC38 tumors expressing the selected neoepitopes and sustained immune memory to prevent relapse. Additionally, these vectors synergized with anti-programmed cell death protein 1 (PD1) therapy to inhibit wild-type MC38 tumor growth. Variant allele frequency tracking demonstrated T cells eradicated neoantigen-positive cells without affecting negative ones. Our results validate lentiviral vectors for personalized neoepitope therapy and underscore the need for diverse neoantigens in immunotherapy against tumor mosaicism.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"143"},"PeriodicalIF":6.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease. 鼻内递送表达新鉴定的鲍曼不动杆菌抗原的mRNA可预防细菌性肺部疾病。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-04 DOI: 10.1038/s41541-025-01202-0

Sophie L Higham, Ziyin Wang, Valarmathy Murugaiah, Jihye Song, Chubicka Thomas, Houze Zhang, Uta Griesenbach, Eric W F W Alton, Luke A Granger, Andrea Flores Esparza, Beatriz Dias Barbieri, Paul G Hitchen, Paul Kellam, Robin J Shattock, Shiranee Sriskandan, Stephen T Reece, John S Tregoning

{"title":"Intranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease.","authors":"Sophie L Higham, Ziyin Wang, Valarmathy Murugaiah, Jihye Song, Chubicka Thomas, Houze Zhang, Uta Griesenbach, Eric W F W Alton, Luke A Granger, Andrea Flores Esparza, Beatriz Dias Barbieri, Paul G Hitchen, Paul Kellam, Robin J Shattock, Shiranee Sriskandan, Stephen T Reece, John S Tregoning","doi":"10.1038/s41541-025-01202-0","DOIUrl":"10.1038/s41541-025-01202-0","url":null,"abstract":"Vaccines are central to the strategy to control antimicrobial resistant (AMR) bacterial infections; one multidrug resistant pathogen of particular concern is Acinetobacter baumannii. In this study we identified two novel A. baumannii antigens using mass spectrometry and phage expression: Oxa23 and PAL. These genes are highly conserved between different isolates of A. baumannii and recognised by convalescent human sera. We explored their protective immunity using two different vaccine platforms, recombinant outer membrane vesicles (rOMV) and mRNA. RNA vaccine immunised mice had significantly reduced bacterial load in their lower airways following challenge with carbapenem resistant A. baumannii, with Oxa23 providing better protection than PAL. We then compared routes of delivery and RNA vaccine platforms, demonstrating that intranasally delivery of mRNA encoding OXA-23 (formulated with GL67A) significantly reduced disease severity and enhanced bacterial clearance. These studies validate in silico identified antigens through challenge studies and novel mucosal vaccine delivery approaches.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"144"},"PeriodicalIF":6.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A field test of empathetic refutational and motivational interviewing to address vaccine hesitancy among patients. 共情反驳和动机访谈的现场测试，以解决疫苗犹豫患者。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-03 DOI: 10.1038/s41541-025-01197-8

Angelo Fasce, Mirela Mustață, Alexandra Deliu, Dawn Holford, Linda Karlsson, Virginia Gould, Gheorghe Gindrovel Dumitra, Dana Farcasanu, Iulia Vișinescu, Pierre Verger, Stephan Lewandowsky

{"title":"A field test of empathetic refutational and motivational interviewing to address vaccine hesitancy among patients.","authors":"Angelo Fasce, Mirela Mustață, Alexandra Deliu, Dawn Holford, Linda Karlsson, Virginia Gould, Gheorghe Gindrovel Dumitra, Dana Farcasanu, Iulia Vișinescu, Pierre Verger, Stephan Lewandowsky","doi":"10.1038/s41541-025-01197-8","DOIUrl":"10.1038/s41541-025-01197-8","url":null,"abstract":"Vaccine hesitancy is among the most concerning public health issues due to declining immunization rates worldwide. We report a mixed-methods field test of two conversational techniques that allow for an empathetic dialogue on vaccination between health care professionals and patients: Empathetic-refutational interviewing (ERI) and motivational interviewing (MI). Thirty Romanian general practitioners were assigned to an untrained control group and to two experimental groups in which they were trained in ERI or MI. After training, physicians had conversations on HPV and influenza vaccines with 334 patients who were hesitant to receive a vaccination. Patients of physicians in the ERI group demonstrated larger increases in positive attitudes toward vaccines and willingness to get vaccinated, while a greater proportion of patients in the MI group scheduled vaccination appointments. Interviews with participating physicians revealed overall satisfaction with the conversational techniques. Empathetic interpersonal communication can have a substantial positive impact on vaccination rates, especially for vaccines subject to mass misinformation campaigns.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"142"},"PeriodicalIF":6.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Humoral immunity is sufficient to protect mice against Rift Valley fever encephalitis following percutaneous exposure. 体液免疫足以保护小鼠免受经皮接触后的裂谷热脑炎。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-02 DOI: 10.1038/s41541-025-01200-2

Karina Mueller Brown, Dominique J Barbeau, Lingqing Xu, Brian H Bird, Anita K McElroy

{"title":"Humoral immunity is sufficient to protect mice against Rift Valley fever encephalitis following percutaneous exposure.","authors":"Karina Mueller Brown, Dominique J Barbeau, Lingqing Xu, Brian H Bird, Anita K McElroy","doi":"10.1038/s41541-025-01200-2","DOIUrl":"10.1038/s41541-025-01200-2","url":null,"abstract":"In humans, Rift Valley fever virus (RVFV) infection typically presents as a self-limiting febrile illness but can cause severe complications. Neurological disease manifestations are particularly concerning as they are associated with increased mortality and long-term morbidity. This study demonstrated that vaccination with live attenuated RVFV was effective in preventing central nervous system (CNS) disease in the CC057/Unc mouse model of late-onset RVF encephalitis. Vaccine candidates (ΔNSs and ΔNSsΔNSm) were safe and immunogenic and elicited both RVFV-specific humoral and cellular immunity. Vaccinated mice survived percutaneous wild-type (WT) RVFV challenge and were protected from CNS disease. Naïve mice that received passive transfer of serum from vaccinated animals 2 days post-WT challenge were protected against late-onset encephalitis. These data demonstrate that humoral immunity is sufficient to protect against RVF encephalitis in CC057/Unc mice and suggest the potential of these vaccine candidates to prevent CNS disease in humans.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"141"},"PeriodicalIF":6.9,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144554040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C. 含新型可电离脂质的SARS-CoV-2 mRNA冻干疫苗在25℃下保存1年后的效力。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-01 DOI: 10.1038/s41541-025-01201-1

Elena Mata, Esther Broset, Carlos Matute, Andrei Stoian, Susana Adame, Teresa Alejo, Alexandre López, Beatriz Andrés, Juan Heredero, Diego de Miguel, Javier Giménez-Warren, Verónica Lampaya, Diego Casabona, Alba Calvo, Gema Quincoces, Iván Peñuelas, Carlos Gamazo, Iratxe Uranga, Natacha Peña, Maykel Arias, Julián Pardo, Bernardino Moreno, Juan Badiola, Juan Martínez-Oliván, Esther Pérez-Herrán

{"title":"Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C.","authors":"Elena Mata, Esther Broset, Carlos Matute, Andrei Stoian, Susana Adame, Teresa Alejo, Alexandre López, Beatriz Andrés, Juan Heredero, Diego de Miguel, Javier Giménez-Warren, Verónica Lampaya, Diego Casabona, Alba Calvo, Gema Quincoces, Iván Peñuelas, Carlos Gamazo, Iratxe Uranga, Natacha Peña, Maykel Arias, Julián Pardo, Bernardino Moreno, Juan Badiola, Juan Martínez-Oliván, Esther Pérez-Herrán","doi":"10.1038/s41541-025-01201-1","DOIUrl":"10.1038/s41541-025-01201-1","url":null,"abstract":"mRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability. In this study, we developed CPVax-CoV, a new lyophilized mRNA vaccine that features novel thiolactone-based ionizable lipids and newly designed untranslated regions (UTRs) for enhanced expression. Incorporation of these optimized components into our vaccine candidate CPVax-CoV significantly improved immune responses in mice compared to commercially available mRNA vaccines. Moreover, lyophilized CPVax-CoV has proven to be thermostable, maintaining its biological activity for up to one year at 4 °C and 25 °C after lyophilization, overcoming the cold-chain limitations of current mRNA vaccines. This vaccine demonstrates protective efficacy against ancestral SARS-CoV-2 and the Omicron XBB variant, offering a scalable solution for global distribution and pandemic preparedness. These findings underscore the potential of this platform for future next-generation mRNA vaccine development.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"135"},"PeriodicalIF":6.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144541611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2. 针对G和M2的单剂量鼻内腺病毒RSV疫苗。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-01 DOI: 10.1038/s41541-025-01186-x

Eunju Jang, Serin Lee, Jiyu Han, Jun Chang

引用次数: 0

Vaccination against COVID-19 and Outcomes in Patients with COVID-19 Infection and Stroke. COVID-19疫苗接种和COVID-19感染和卒中患者的预后

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-01 DOI: 10.1038/s41541-025-01158-1

Nader El Seblani, Maria P Gorenflo, Santiago Ortega-Gutierrez, Raymond K Reichwein, Rong Xu, Nandakumar Nagaraja

{"title":"Vaccination against COVID-19 and Outcomes in Patients with COVID-19 Infection and Stroke.","authors":"Nader El Seblani, Maria P Gorenflo, Santiago Ortega-Gutierrez, Raymond K Reichwein, Rong Xu, Nandakumar Nagaraja","doi":"10.1038/s41541-025-01158-1","DOIUrl":"10.1038/s41541-025-01158-1","url":null,"abstract":"We aimed to determine the clinical impact of prior vaccination against Coronavirus Disease 2019 (COVID-19) on COVID-19 infection associated acute ischemic stroke (AIS). Using the TriNetX COVID-19 Research Network, an international electronic health record database, we identified AIS cases admitted between April 1, 2021 and September 30, 2022 that had a COVID-19 diagnosis up to 30 days before hospitalization. The study cohort was divided into two groups: those with and without vaccination against COVID-19. The two groups were matched for demographics, comorbidities, and antithrombotics taken before AIS with 1:1 propensity score matching. Cox proportional hazard analysis was performed to report primary (all-cause mortality) and secondary outcomes at 7 and 30 days after AIS. We identified 3,573 vaccinated (71 ± 12 (mean ± SD) years, 49% females) and 46,329 unvaccinated patients (65 ± 15 years, 45% females) who met the study criteria. After propensity score matching, 3,569 patients were in both groups. Vaccinated individuals had significantly lower rates of all-cause mortality [7 days: 3.3% vs 5.0%; HR = 0.66; 95% CI = 0.52-0.83 and 30 days: 8.2% vs 9.5%; HR = 0.83; 95% CI = 0.71-0.97], intracranial hemorrhage [7 days: 4.1% vs 6.2%; HR = 0.66; 95% CI = 0.53-0.82 and 30 days: 4.5% vs 6.7%; HR = 0.66; 95%CI = 0.53-0.81], venous thromboembolism [7 days: 3.5% vs 7.8%; HR = 0.44; 95% CI = 0.35-0.56 and 30-days: 4.6% vs 8.9%; HR = 0.51; 95% CI = 0.41-0.63] and acute myocardial infarction [7 days: 4.1% vs 7.0%; HR = 0.58; 95% CI = 0.46-0.73 and 30 days: 4.7% vs 7.6%; HR = 0.60; 95% CI = 0.49-0.75)]. Prior vaccination against COVID-19 is associated with reduced rates of all-cause mortality, intracranial hemorrhage, venous thromboembolism, and acute myocardial infarction within 30 days of COVID-19 associated AIS.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"133"},"PeriodicalIF":6.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12216920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144541614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0